Note: Poly MVA does not require a prescription.
For Maximum Effectiveness – How and When to Take Poly-MVA:
Pets: To disguise Poly-MVA taste or for administration to unwilling animals, Poly-MVA may be
sprayed via a syringe down the throat or mixed in with liquids (meat broth) or wet dog foods.
There appear to be no contraindications with Poly-MVA thus far. Used as an adjuvant therapy,
concurrently with primary conventional therapies such as chemotherapy, radiation, and surgery,
no contraindications are known at this time.
LUNG CANCER – Animals prone to pleural effusion require careful monitoring by a veterinarian,
since fluid accumulation may increase with the administration of Poly-MVA due to cell die off
resulting in increased fluid in the lungs. Decrease or discontinue dosage until fluid has decreased.
METASTASIS & HIGH TUMOR LOAD – For those patients with metastasis or a high tumor load, you
may see a dramatic increase in their tumor marker tests. These tests can not differentiate
between a live or dead cell that is circulating in the blood. Therefore, a large tumor load in
conjunction with a high daily dosage of Poly-MVA may result in the accumulation of dead cancer
cells in the blood which may cause an increase in tumor markers. Detoxification is critical to
eliminate the systemic build up in the blood and liver.
* Tumor markers may become elevated due to rapid cell die off.
HEALING CRISIS – A “detoxification reaction,” or “healing crisis,” may be due to the accumulation
of debris caused by cancer cell die off. When this occurs, these dead cancer cells may stimulate an
immune response which can result in a healing crisis. Reduce dosage until the symptoms
disappear. Symptoms may include, increase in tumor markers, rash, unusual or strong body
odors, diarrhea, fatigue, nausea, or a temporary worsening of existing conditions.
Clinical Human and Veterinary Studies
* Veterinary – The largest integrative cancer investigation of PdLA was an open-label, veterinary
oncology program with over 900 dogs enrolled, since its inception in January 2004. Patients
received the PdLA supplement POLY-MVA as part of their treatments at a dosage of 1mL/5 lbs.
P.O. twice daily (equivalent human dose of approximately 8 tsp.). The PdLA seemed most effective
in the cases of solid tumors (i.e. soft tissue sarcoma, hemangiosarcoma, mast cell, transition cell
carcinoma, lung, anal sac carcinoma, renal carcinoma, squamous cell carcinoma, fibrosarcoma,
melanoma, menigioma, neuroblastoma, mammary adenocarcinoma). Some of the most effective
findings were apparent in the osteosarcoma patients.
The etiology of osteosarcoma in large dogs
is considered identical to the disease progression in humans. While in canines the “standard of
care” is limb amputation followed by chemotherapy, in human patients, limb– sparing surgery
following tumor excision is performed (Ogilvie and Moore, 2006). In this open labeled study,
integrative PdLA support (PdLA + amputation) improved the animals’ median survival time 62%
(103 days more) compared to surgery alone (n= 11 and 162, respectively). When the PdLA
supplement was added to the chemotherapeutic regimen (carboplatin + doxorubicin) the dogs
exhibited a 27% longer median survival (79 days more) (n= 32 amputation with chemotherapy;
n= 17 amputation + chemotherapy + Poly MVA). Furthermore, there was no significant difference
(p=0.30) in median survival time between dogs treated with amputation + Poly MVA versus those
that were treated with amputation + the “standard of care” chemotherapy.
* Veterinary – It is important to note that following PdLA complementary support,
chemotherapeutic animals demonstrated improvements in various objective parameters (i.e.
weight, anemia, liver and kidney function). In addition to these enhanced clinical parameters, a
subjective owner-based quality of life survey resulted in an 86% improvement for pets following
the addition of PdLA adjunctive support.
“I would not be involved with Poly-MVA research if I did not
believe it would
help a majority of my patients experience an improved quality of
Gregory K. Ogilvie, DVM
“He is your
friend, your partner, your defender, your dog [or cat]. You are
his life, his love, his leader. He will be
yours, faithful and true, to the last beat of his heart. You owe
it to him to be worthy of such devotion.”